Literature DB >> 18001255

Drug interactions in the management of HIV infection: an update.

Sarah M Robertson1, Scott R Penzak, Alice Pau.   

Abstract

Improvement in the availability of antiretroviral (ARV) therapy continues to reduce HIV morbidity and mortality. With more treatment choices and better accessibility, the extent of medication use among patients with HIV/AIDS continues to grow. ARV drugs are particularly prone to drug interactions as a consequence of their metabolic and pharmacokinetic properties. The recognition and management of drug interactions in patients on ARVs is a constant challenge to medical providers. Staying abreast of drug interaction knowledge is complicated by the rate at which new information becomes available through in vivo investigation, case reports and pharmacokinetic studies. In addition, distinguishing the clinical significance of an interaction is difficult due to the large interpatient variability in pharmacokinetics exhibited by most ARV agents. This review provides an update to a previous review article published in 2005, and is intended to improve the reader's knowledge of drug interactions in the management of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001255     DOI: 10.1517/14656566.8.17.2947

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

Review 1.  Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Authors:  Gail D Anderson; Lingtak-Neander Chan
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

2.  Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Authors:  Catherine Orrell; Karen Cohen; Francesca Conradie; Jennifer Zeinecker; Prudence Ive; Ian Sanne; Robin Wood
Journal:  Antivir Ther       Date:  2011

3.  Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Authors:  Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Journal:  Drug Alcohol Depend       Date:  2009-02-18       Impact factor: 4.492

Review 4.  The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infection.

Authors:  R F Ambinder
Journal:  Bone Marrow Transplant       Date:  2009-05-18       Impact factor: 5.483

5.  Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Authors:  Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

6.  Improving the self-report of HIV antiretroviral medication adherence: is the glass half full or half empty?

Authors:  Ira B Wilson; Amanda E Carter; Karina M Berg
Journal:  Curr HIV/AIDS Rep       Date:  2009-11       Impact factor: 5.071

7.  Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington; Alysa Walker; Pamela Sheffels Bedynek
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

8.  Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Authors:  Michael Neely; Roger Jelliffe
Journal:  J Clin Pharmacol       Date:  2008-07-17       Impact factor: 3.126

9.  Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

Authors:  Gabriel Kigen; Sylvester Kimaiyo; Winstone Nyandiko; Brian Faragher; Edwin Sang; Beatrice Jakait; Andrew Owen; David Back; Sara Gibbons; Kay Seden; Saye H Khoo
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

10.  Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.

Authors:  Daniel W Gunda; Christa Kasang; Benson R Kidenya; Rodrick Kabangila; Stephen E Mshana; Jeremiah Kidola; Samuel E Kalluvya; Gilbert W Kongola; Hartwig Klinker
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.